Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Okay, when do we hear back from the FDA regarding the partial hold and the interim look? Should be getting close, I believe.
Haven't all of them?
I got the info from fintel.
https://fintel.io/so/us/adxs
Forgot that Deutsche Bank bought 553,031 shares on 4/1.
Empery Asset Mgmnt, Frigate Ventures and Shabby Mgmnt each bought 600,000 shares.
All sites are up and running. It's in the best interests of Aratana to wrap it up. If you google information about the vaccine, there's a lot of articles about it.
Latest ownership per Fintel: https://fintel.io/so/us/adxs
Part A Median = 7.8 months
Part B Median = 21.1 months
That's a pretty good difference. The median OS for those with PSA reduction ≥50% from BL (Part B) had not been reached at the data cutoff point. I would like to see how long it takes to reach that median.
Hov, do you an idea how long an extended field safety study like Aratana's should/would take? I know all he sites are up and running.
I think it's more of a safety study. I was hoping it could be done in about a year. All 24 sites are up and running.
We should be getting close to a decision. Aratana should also be wrapping up their extended field study, I believe.
There will always be new treatments. Most of what is still in development now may be obsolete in a few years. A product used as an adjunctive therapy, however, may always have a place in medicine. JMO.
Actually, I think one of the values of LM tech is it can be combined with almost anything out there. If it can increase efficacy of other treatments, that can add tremendous worth to it.
I read the job descriptions and wasn't sure what to make of them but I did want to post the link.
I felt the same way but a link was asked for.
I think it was fair to say we all knew this was coming. I don't like it but it was not unexpected. KB never should have opened his mouth about the term sheets, either. It is like the time DOC said he thought this could be a $50 stock in a couple of years. A few weeks ago 50 cents seemed like a good deal.
According to NASDAQ, there are now 4,649,000 shares outstanding.
But you said it would close red.
benzinga news sentiment bullish 84% positive.
weeeee
"Conclusions: ADXS-PSA ± pembro elicited a broad antitumor T cell response in all mCRPC pts tested but only ADXS-PSA + pembro reduced PSA ≥50% from BL and prolonged OS in these select pts."
AF willfully ignored including this last paragraph from the article he sited.
Thank you for being one of the voices of reason and sanity here. Obviously, neither Amgen nor Merck had enough clinical evidence to assess the efficacy of the treatments despite the claims of others. I'm hoping more light is shed on the responses of the six patients. There appear to be a number of patients (23) in Part B <50% PSA decline from baseline (according to the slide on the CP) who had not had an event, also. Would to hear an update on them.
You raise excellent questions. Looking at slide 16 on the CP, it appears the data cutoff date is 3/30/2018. So does this mean the graph shows approx. 12 months since the trial started A/O 3/30/2018 for the Part B >? From the AACR abstract, "Median OS in PB pts with PSA reduction ≥50% from BL has not been reached as 100% (6/6) of pts are still alive." Alive as of what date, is what I want to know. Perhaps, the PR (Monday?) will answer some of the questions.
"Abstract submission deadline: Thursday, January 10"
Assuming they were prepared before the deadline date, 3 months old, or so.
Agree.
I think the prostate data is (all 6 pts. with PSA reduction ≥50% from BL has not been reached as 100% (6/6) of pts are still alive.)
I also liked this part for NEO,
“Median OS in PB pts with PSA reduction ≥50% from BL has not been reached as 100% (6/6) of pts are still alive.”
That is very pleasant news.
Where is fbg?
Image from Sept. 2011?
I'd like to see a steady climb up going into AACR and (if good or better results) a continued climb thereafter.
Holding.
So, is this good, bad, nobody knows?
Well, appears to be up pre-market.
I think it's safe to sat the trading action the past week or so has been unusual. The old adage is volume precedes price. Let's see if this holds going into the new week.
I think most here would like to see that.